Koch B D, Schonbrunn A
Laboratory of Toxicology, Harvard School of Public Health, Boston, Massachusetts 02115.
J Biol Chem. 1988 Jan 5;263(1):226-34.
The neuropeptide somatostatin inhibits prolactin release from GH4C1 pituitary cells via two mechanisms, inhibition of stimulated adenylate cyclase activity and an undefined cAMP-independent process. Somatostatin also hyperpolarizes GH4C1 cells and reduces their intracellular free Ca2+ concentration ([Ca2+]i) in a cAMP-independent manner. To determine whether these ionic changes were involved in the cAMP-independent mechanism by which somatostatin inhibited secretion, changes in cAMP levels were prevented from having any biological consequences by performing experiments in the presence of a maximal concentration of a cAMP analog. Under these conditions, inhibition of prolactin release by somatostatin required a transmembrane concentration gradient for K+ but not one for either Na+ or Cl-. However, elimination of the outward K+ gradient did not prevent somatostatin inhibition of vasoactive intestinal peptide-stimulated hormone release. Therefore, somatostatin's cAMP-mediated mechanism does not require a K+ gradient, whereas its cAMP-independent inhibition of secretion appears to result from a change in K+ conductance. Consistent with this conclusion, membrane hyperpolarization with gramicidin (1 microgram/ml) mimicked somatostatin inhibition of prolactin release. In addition, the K+ channel blocker tetrabutylammonium prevented the effects of somatostatin on the membrane potential, the [Ca2+]i and hormone secretion. Nonetheless, a K+ gradient was not sufficient for somatostatin action. Even in the presence of a normal K+ gradient, somatostatin was only able to inhibit prolactin release when the extracellular Ca2+ concentration was at least twice the [Ca2+]i. Furthermore, the calcium channel blocker, nifedipine (10 microM), which prevents the action of somatostatin to reduce the [Ca2+]i, specifically blocked inhibition of prolactin release via somatostatin's cAMP-independent mechanisms. Therefore, a decrease in Ca2+ influx through voltage-dependent Ca2+ channels produces both the fall in [Ca2+]i and inhibition of hormone secretion in response to somatostatin.
神经肽生长抑素通过两种机制抑制GH4C1垂体细胞释放催乳素,即抑制刺激的腺苷酸环化酶活性和一种未知的非cAMP依赖过程。生长抑素还能使GH4C1细胞超极化,并以非cAMP依赖的方式降低其细胞内游离Ca2+浓度([Ca2+]i)。为了确定这些离子变化是否参与生长抑素抑制分泌的非cAMP依赖机制,通过在最大浓度的cAMP类似物存在下进行实验,防止cAMP水平变化产生任何生物学后果。在这些条件下,生长抑素抑制催乳素释放需要K+的跨膜浓度梯度,但不需要Na+或Cl-的浓度梯度。然而,消除外向K+梯度并不能阻止生长抑素抑制血管活性肠肽刺激的激素释放。因此,生长抑素的cAMP介导机制不需要K+梯度,而其非cAMP依赖的分泌抑制似乎是由K+电导变化引起的。与这一结论一致,短杆菌肽(1微克/毫升)引起的膜超极化模拟了生长抑素对催乳素释放的抑制作用。此外,K+通道阻滞剂四丁铵可阻止生长抑素对膜电位、[Ca2+]i和激素分泌的影响。尽管如此,K+梯度不足以实现生长抑素的作用。即使在存在正常K+梯度的情况下,只有当细胞外Ca2+浓度至少是[Ca2+]i的两倍时,生长抑素才能抑制催乳素释放。此外,钙通道阻滞剂硝苯地平(10微摩尔)可阻止生长抑素降低[Ca2+]i的作用,特异性地阻断生长抑素通过其非cAMP依赖机制对催乳素释放的抑制。因此,通过电压依赖性Ca2+通道的Ca2+内流减少既导致[Ca2+]i下降,也导致对生长抑素的激素分泌抑制。